Brevan Howard Capital Management’s Regenxbio RGNX Stock Holding History

Brevan Howard Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$158K	Buy	18,902 +2,062	+12%	+$21.7K	﹤0.01%	1951
2025 Q4	$242K	Buy	16,840 +448	+3%	+$5.58K	﹤0.01%	1484
2025 Q3	$158K	Buy	+16,392	New	+$145K	﹤0.01%	1803
2025 Q2	–	Sell	-17,373	Closed	-$124K	–	1985
2025 Q1	$124K	Sell	17,373 -23,787	-58%	-$177K	﹤0.01%	1037
2024 Q4	$318K	Buy	+41,160	New	+$386K	﹤0.01%	753
2024 Q3	–	Sell	-15,222	Closed	-$178K	–	1387
2024 Q2	$178K	Buy	+15,222	New	+$237K	﹤0.01%	916

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's RGNX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Regenxbio (RGNX) stake by 12% in Q1 2026, buying an estimated $21.7K and bringing the position to 18,902 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Brevan Howard Capital Management first reported a position in RGNX in Q2 2024 and has held it in 6 quarters since. The position peaked at $318K in Q4 2024. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Brevan Howard Capital Management held 18,902 shares of Regenxbio worth $158K as of Q1 2026.
Brevan Howard Capital Management bought 2,062 Regenxbio shares in Q1 2026, an estimated $21.7K.
Regenxbio made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1951 holding.
Brevan Howard Capital Management first reported a position in Regenxbio in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Regenxbio position peaked at $318K in Q4 2024.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.